Investment Rating - The investment rating for the company is "Buy" and is maintained [7] Core Insights - The company achieved a net profit of 2.15 billion, representing a year-on-year increase of 46%, which aligns with expectations [1] - Revenue for the year 2024 is projected to be 5.54 billion, a year-on-year increase of 57%, with a net profit of 2.06 billion, up 42% [1] - The company is expected to continue its growth trajectory, with revenue forecasts of 7.07 billion, 8.71 billion, and 10.45 billion for 2025, 2026, and 2027 respectively, reflecting year-on-year growth rates of 28%, 23%, and 20% [5] Financial Performance - The adjusted net profit for 2024 is projected at 2.15 billion, a 46% increase year-on-year, which meets expectations [1] - The gross margin for 2024 is 82.1%, a decrease of 1.5 percentage points year-on-year, while the net profit margin is 37.2%, down 4 percentage points [2] - The company plans to distribute a total dividend of 1.19 per share, with a payout ratio of 60% [1] Business Segmentation - The main brand, Kefu Mei, generated revenue of 4.54 billion, a year-on-year increase of 63%, accounting for 82% of total revenue [3] - Online sales accounted for 72% of total revenue, with a year-on-year growth of 70% [3] - The second brand, Keli Jin, saw revenue of 840 million, a 36% increase year-on-year [3] Future Outlook - The company is positioned as a leader in the collagen protein sector, with strong growth in its main brand and accelerating growth in its second brand [5] - The company is expected to maintain a strong market presence with significant online sales growth and expansion into new retail locations [4]
巨子生物（02367）：24年年报点评：可复美延续高增势能超预期，子品牌可丽金提速未来可期